Compare RNTX & HOVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RNTX | HOVR |
|---|---|---|
| Founded | 2001 | 2013 |
| Country | United States | Canada |
| Employees | 10 | 30 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 89.0M | 80.6M |
| IPO Year | N/A | N/A |
| Metric | RNTX | HOVR |
|---|---|---|
| Price | $0.93 | $1.70 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $10.00 | ★ $10.33 |
| AVG Volume (30 Days) | 579.2K | ★ 997.1K |
| Earning Date | 05-15-2026 | 04-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $1.16 |
| 52 Week High | $2.18 | $4.18 |
| Indicator | RNTX | HOVR |
|---|---|---|
| Relative Strength Index (RSI) | 43.90 | 35.01 |
| Support Level | $0.85 | $1.20 |
| Resistance Level | $1.05 | $1.91 |
| Average True Range (ATR) | 0.07 | 0.12 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 33.74 | 6.67 |
Rein Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing novel therapies for the treatment of orphan pulmonary and fibrosis indications with no approved or limited effective treatments. Its pipeline includes: LTI-03, a peptide, for placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis, that has demonstrated the ability to protect healthy lung epithelial cells and reduce pro-fibrotic signaling; LTI-01, a proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment.
New Horizon Aircraft Ltd is an aerospace Original Equipment Manufacturer that is designing and building a next-generation hybrid electric vertical take-off and landing aircraft for the regional air mobility market. Its aircraft will offer a more efficient way to move people and goods at a regional scale, help to connect remote communities, and advance its ability to deal with an increasing number of climate-related natural disasters such as wildfires, floods, and droughts. The company aims to deliver a hybrid electric 7-seat aircraft, called the Cavorite X7, that can take off and land vertically like and helicopter.